Yarrow Bioscience, Inc.
YARW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001566044
No open-market purchases or sales by Yarrow Bioscience, Inc. insiders were filed in the last 90 days; 46 institutions reported holding it in 13F filings for Q2 2026, worth $8.79M in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in Yarrow Bioscience, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 38
- +3 vs. Q4 2024
- Shares held
- 7.16M
- +97.0K (+1.4%) vs. Q4 2024
- Total value
- $11.5M
- −$12.0M (−51.0%) vs. Q4 2024
- New holders
- 7
- 15 more added
- Sold out
- 4
- 7 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting YARW on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 46 | $8.79M |
| Q1 2026 | 46 | $8.49M |
| Q4 2025 | 45 | $5.35M |
| Q3 2025 | 36 | $1.33M |
| Q2 2025 | 46 | $13.4M |
| Q1 2025 | 38 | $11.5M |
| Q4 2024 | 35 | $23.4M |
| Q3 2024 | 33 | $14.3M |
| Q2 2024 | 32 | $16.1M |
| Q1 2024 | 32 | $22.9M |
| Q4 2023 | 33 | $18.4M |
| Q3 2023 | 21 | $1.54M |
| Q2 2023 | 20 | $1.63M |
| Q1 2023 | 23 | $1.10M |
| Q4 2022 | 41 | $1.10M |
| Q3 2022 | 41 | $1.84M |
| Q2 2022 | 41 | $3.25M |
| Q1 2022 | 45 | $5.63M |
| Q4 2021 | 55 | $12.5M |
| Q3 2021 | 65 | $20.1M |
| Q2 2021 | 73 | $64.0M |
| Q1 2021 | 87 | $152.4M |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Yarrow Bioscience, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Truvestments Capital LLC | 25 | $40 | 0.00% | +25 | New |
| Wells Fargo & Company | 65 | $103 | 0.00% | 00.0% | Unchanged |
| CWM, LLC | 500 | $1.00K | 0.00% | 00.0% | Unchanged |
| Centerpoint Advisors, LLC | 350 | $1.00K | 0.00% | 00.0% | Unchanged |
| MB, Levis & Associates, LLC | 1,041 | $1.65K | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 2,440 | $4.00K | 0.00% | −22,789−90.3% | Reduced |
| Tower Research Capital LLC (TRC) | 4,296 | $6.79K | 0.00% | +2,910+210.0% | Added |
| JPMorgan Chase & Co | 5,981 | $9.45K | 0.00% | +5,667+1,804.8% | Added |
| UBS Group AG | 7,576 | $12.0K | 0.00% | +6,945+1,100.6% | Added |
| Morgan Stanley | 12,811 | $20.2K | 0.00% | +8,512+198.0% | Added |
| State Street Corp | 15,765 | $24.9K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 17,163 | $27.1K | 0.00% | +15,672+1,051.1% | Added |
| Shay Capital LLC | 18,015 | $28.5K | 0.01% | +18,015 | New |
| Commonwealth Equity Services, LLC | 18,298 | $29.0K | 0.00% | 00.0% | Unchanged |
| Virtu Financial LLC | 19,574 | $31.0K | 0.00% | +19,574 | New |
| Northern Trust Corp | 23,971 | $37.9K | 0.00% | 00.0% | Unchanged |
| HRT Financial LP | 26,242 | $41.0K | 0.00% | +26,242 | New |
| XTX Topco Ltd | 33,052 | $52.2K | 0.00% | +12,034+57.3% | Added |
| UBS Oconnor LLC | 45,557 | $72.0K | 0.00% | −200,243−81.5% | Reduced |
| Staley Capital Advisers Inc | 51,472 | $81.3K | 0.00% | +15,000+41.1% | Added |
| Bridgeway Capital Management, LLC | 51,958 | $82.1K | 0.00% | +15,000+40.6% | Added |
| Susquehanna International Group, LLP | 57,762 | $91.3K | 0.00% | −13,070−18.5% | Reduced |
| ADAR1 Capital Management, LLC | 70,419 | $111.3K | 0.02% | +70,419 | New |
| BlackRock, Inc. | 82,579 | $130.5K | 0.00% | −735−0.9% | Reduced |
| Schonfeld Strategic Advisors LLC | 84,978 | $134.3K | 0.00% | −91,680−51.9% | Reduced |
| Renaissance Technologies LLC | 115,143 | $181.9K | 0.00% | +90,200+361.6% | Added |
| Geode Capital Management, LLC | 133,490 | $210.9K | 0.00% | −1,527−1.1% | Reduced |
| Prelude Capital Management, LLC | 141,502 | $223.6K | 0.02% | +82,102+138.2% | Added |
| Parkman Healthcare Partners LLC | 217,978 | $344.4K | 0.04% | +65,005+42.5% | Added |
| Patient Square Capital LP | 257,033 | $406.1K | 0.17% | +257,033 | New |
| Adage Capital Partners GP, L.L.C. | 344,134 | $543.7K | 0.00% | +190,000+123.3% | Added |
| Palo Alto Investors LP | 445,434 | $703.8K | 0.13% | 00.0% | Unchanged |
| Exome Asset Management LLC | 462,801 | $731.2K | 0.65% | +109,367+30.9% | Added |
| Vanguard Group Inc | 475,650 | $751.5K | 0.00% | +521+0.1% | Added |
| DAFNA Capital Management LLC | 636,103 | $1.01M | 0.28% | +636,103 | New |
| Acorn Capital Advisors, LLC | 785,938 | $1.24M | 0.83% | +328,968+72.0% | Added |
| Citadel Advisors LLC | 1,100,329 | $1.74M | 0.00% | −130,128−10.6% | Reduced |
| Eventide Asset Management, LLC | 1,394,336 | $2.37M | 0.05% | 00.0% | Unchanged |
| Cormorant Asset Management, LP | 0 | $0 | 0.00% | −1,394,336−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −20,286−100.0% | Sold out |
| BFSG, LLC | 0 | $0 | 0.00% | −3,500−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −5−100.0% | Sold out |